{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:27:17Z","timestamp":1790504837362,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T00:00:00Z","timestamp":1572220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T00:00:00Z","timestamp":1572220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The advent of effective direct-acting antivirals (DAAs), has prompted an assessment of the French Hepatitis C virus (HCV) screening strategy, which historically targeted high-risk groups. One of the options put forward is the implementation of combined (i.e., simultaneous) HCV, Hepatitis B virus (HBV) and HIV screening for all adults at least once during their lifetime (\u201cuniversal combined screening\u201d). However, recent national survey-based data are lacking to guide decision-making regarding which new strategy to implement. Accordingly, we aimed to provide updated data for both chronic hepatitis C (CHC) and B (CHB) prevalence and for HCV and HBV screening history, using data from the BaroTest and 2016 Health Barometer (2016-HB) studies, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>2016-HB was a national cross-sectional phone based health survey conducted in 2016 among 20,032 randomly selected individuals from the general population in mainland France. BaroTest was a virological sub-study nested in 2016-HB. Data collected for BaroTest were based on home blood self-sampling on dried blood spots (DBS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 6945 analyzed DBS, chronic hepatitis C (CHC) and B (CHB) prevalence was estimated at 0.30% (95% Confidence Interval (CI): 0.13-0.70) and 0.30% (95% CI: 0.13-0.70), respectively. The proportion of individuals aware of their status was estimated at 80.6% (95% CI: 44.2-95.6) for CHC and 17.5% (95% CI: 4.9-46.4) for CHB. Universal combined screening would involve testing between 32.6 and 85.3% of 15-75\u2009year olds according to whether we consider only individuals not previously tested for any of the three viruses, or also those already tested for one or two of the viruses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data are essential to guide decision-making regarding which new HCV screening recommendation to implement in France. They also highlight that efforts are still needed to achieve the WHO\u2019s targets for eliminating these diseases. Home blood self-sampling may prove to be a useful tool for screening and epidemiological studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-019-4493-2","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T09:10:58Z","timestamp":1572253858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["HCV and HBV prevalence based on home blood self-sampling and screening history in the general population in 2016: contribution to the new French screening strategy"],"prefix":"10.1186","volume":"19","author":[{"name":"the 2016 Health Barometer Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-7400","authenticated-orcid":false,"given":"C\u00e9cile","family":"Brouard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le\u00efla","family":"Saboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Chevaliez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Rahib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Barin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Sommen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josiane","family":"Pillonel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Delarocque-Astagneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Lydi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Lot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,28]]},"reference":[{"key":"4493_CR1","unstructured":"World Health Organization. Global hepatitis report, 2017. \n                    http:\/\/apps.who.int\/iris\/bitstream\/10665\/255016\/1\/9789241565455-eng.pdf?ua=1\n                    \n                  . Accessed 1 Dec 2018."},{"key":"4493_CR2","unstructured":"World Health Organization. Global health sector strategy on HIV, 2016-2021. Towards ending AIDS. \n                    http:\/\/www.who.int\/hiv\/strategy2016-2021\/ghss-hiv\/en\/\n                    \n                  . Accessed 1 Dec 2018."},{"key":"4493_CR3","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. \n                    http:\/\/apps.who.int\/iris\/bitstream\/10665\/246177\/1\/WHO-HIV-2016.06-eng.pdf?ua=1\n                    \n                  . Accessed 1 Dec 2018."},{"key":"4493_CR4","unstructured":"Pioche C, Pelat C, Larsen C, Desenclos JC, Jauffret Roustide M, Lot F, et al. Estimation de la pr\u00e9valence de l'h\u00e9patite C en population g\u00e9n\u00e9rale, France m\u00e9tropolitaine, 2011. Num\u00e9ro th\u00e9matique. H\u00e9patites B et C, donn\u00e9es \u00e9pid\u00e9miologiques r\u00e9centes. Bull Epidemiol Hebd. 2016;13-14:224\u20139."},{"key":"4493_CR5","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/jmv.21734","volume":"82","author":"C Meffre","year":"2010","unstructured":"Meffre C, Le Strat Y, Delarocque-Astagneau E, Dubois F, Antona D, Lemasson JM, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol. 2010;82:546\u201355.","journal-title":"J Med Virol"},{"key":"4493_CR6","unstructured":"Marty L, Cazein F, Lot F, Costagliola D, Supervie V. Nouvelles estimations de la pr\u00e9valence de l\u2019infection \u00e0 VIH. Paris: R\u00e9union Journ\u00e9e mondiale de lutte contre le Sida; 2018."},{"key":"4493_CR7","doi-asserted-by":"publisher","first-page":"e0126920","DOI":"10.1371\/journal.pone.0126920","volume":"10","author":"C Brouard","year":"2015","unstructured":"Brouard C, Le Strat Y, Larsen C, Jauffret-Roustide M, Lot F, Pillonel J. The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014. PLoS One. 2015;10:e0126920.","journal-title":"PLoS One"},{"key":"4493_CR8","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1111\/liv.13135","volume":"36","author":"J Bottero","year":"2016","unstructured":"Bottero J, Brouard C, Roudot-Thoraval F, Deuffic-Burban S, Hofliger P, Abergel A, et al. 2014 French guidelines for hepatitis B and C screening: a combined targeted and mass testing strategy of chronic viruses namely HBV, HCV and HIV. Liver Int. 2016;36:1442\u20139.","journal-title":"Liver Int"},{"key":"4493_CR9","unstructured":"Cazein F, Le Strat Y, Sarr A, Ramus C, Bouche N, Comboroure JC, et al. D\u00e9pistage de l'infection par le VIH en France en 2016. Num\u00e9ro th\u00e9matique. Journ\u00e9e mondiale du sida, 1er d\u00e9cembre 2017. Bull Epidemiol Hebd. 2017;29-30:601\u20138."},{"key":"4493_CR10","unstructured":"Pioche C, L\u00e9on L, Vaux S, Brouard C, Lot F. D\u00e9pistage des h\u00e9patites B et C en France en 2016, Nouvelle \u00e9dition de l\u2019enqu\u00eate LaboHep. Bull Epidemiol Hebd. 2018;11:188\u201395."},{"key":"4493_CR11","unstructured":"Haute autorit\u00e9 de sant\u00e9. R\u00e9\u00e9valuation de la strat\u00e9gie de d\u00e9pistage de l\u2019infection \u00e0 VIH en France. 2017.\u00a0\n                    https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2017-03\/dir2\/reevaluation_de_la_strategie_depistage_vih_-_synthese_conclusions_reco.pdf\n                    \n                  . Accessed 1 Dec 2018."},{"key":"4493_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013132","volume":"5","author":"Y Yazdanpanah","year":"2010","unstructured":"Yazdanpanah Y, Sloan CE, Charlois-Ou C, Le Vu S, Semaille C, Costagliola D, et al. Routine HIV screening in France: clinical impact and cost-effectiveness. PLoS One. 2010;5:e13132.","journal-title":"PLoS One"},{"key":"4493_CR13","unstructured":"Agence nationale d'accr\u00e9ditation et d'\u00e9valuation en sant\u00e9. D\u00e9pistage de l'h\u00e9patite C - Populations \u00e0 d\u00e9pister et modalit\u00e9s du d\u00e9pistage. Recommandations du comit\u00e9 d'experts r\u00e9uni par l'ANAES. 2001.\u00a0\n                    http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/hepatite.pdf\n                    \n                  . Accessed 1 Dec 2018."},{"key":"4493_CR14","unstructured":"Agence nationale d'accr\u00e9ditation et d'\u00e9valuation en sant\u00e9. Diagnostic et suivi virologiques des h\u00e9patites virales (\u00e0 l'exclusion du d\u00e9pistage en cas de dons de sang, d'organes ou de tissus). 2001.\u00a0\n                    https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/Hepatites_virales_recos.pdf\n                    \n                  . Accessed 1 Dec 2018."},{"key":"4493_CR15","doi-asserted-by":"crossref","unstructured":"Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The lancet Gastroenterol Hepatol. 2018;3:383\u2013403.","DOI":"10.1016\/S2468-1253(18)30056-6"},{"key":"4493_CR16","doi-asserted-by":"crossref","unstructured":"Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The lancet Gastroenterol Hepatol. 2017;2:161\u201376.","DOI":"10.1016\/S2468-1253(16)30181-9"},{"key":"4493_CR17","doi-asserted-by":"crossref","unstructured":"European\u00a0Union\u00a0HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. The lancet Gastroenterol Hepatol. 2017;2:325\u2013336.","DOI":"10.1016\/S2468-1253(17)30045-6"},{"key":"4493_CR18","unstructured":"Haute autorit\u00e9 de sant\u00e9. Prise en charge de l'h\u00e9patite C par les m\u00e9dicaments anti-viraux \u00e0 action directe (AAD). Elargissement du p\u00e9rim\u00e8tre de remboursement. 2016.\u00a0\n                    https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2016-12\/recommandation_college_hepatite_c.pdf\n                    \n                  . Accessed 2 Dec 2018."},{"key":"4493_CR19","unstructured":"Haute autorit\u00e9 de sant\u00e9. Feuille de route. Evaluation des strat\u00e9gies de d\u00e9pistage des personnes infect\u00e9es par le VHC (volet 1). 2018.\u00a0\n                    https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2018-11\/feuille_de_route_evaluation_strategies_depistage_vhc_vf_2018-11-28_15-43-5_301.pdf\n                    \n                  . Accessed 2 Dec 2018."},{"key":"4493_CR20","unstructured":"Minist\u00e8re des Affaires sociales et de la Sant\u00e9. Prise en charge th\u00e9rapeutique et suivi de l'ensemble des personnes infect\u00e9es par le virus de l'h\u00e9patite C. Rapport de recommandations 2016. Sous la direction du Pr Daniel Dhumeaux. Sous l'\u00e9gide de l'ANRS et du CNS et avec le concours de l'AFEF. \n                    http:\/\/social-sante.gouv.fr\/IMG\/pdf\/rapport_.pdf\n                    \n                  . Accessed 1 Dec 2018."},{"key":"4493_CR21","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.jhep.2018.05.027","volume":"69","author":"S Deuffic-Burban","year":"2018","unstructured":"Deuffic-Burban S, Huneau A, Verleene A, Brouard C, Pillonel J, Le Strat Y, et al. Assessing the cost-effectiveness of hepatitis C screening strategies in France. J Hepatol. 2018;69:785\u201392.","journal-title":"J Hepatol"},{"issue":"10","key":"4493_CR22","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.2196\/resprot.9797","volume":"7","author":"Nathalie Lydi\u00e9","year":"2018","unstructured":"Lydi\u00e9 N, Saboni L, Gautier A, Brouard C, Chevaliez S, Barin F, et al. Innovative approach for enhancing testing of HIV, hepatitis B, and hepatitis C in the general population: protocol for an acceptability and feasibility study (BaroTest 2016). JMIR Res Protoc. 2018;7:e180.","journal-title":"JMIR Research Protocols"},{"key":"4493_CR23","unstructured":"Richard J-B, Andler R, Gautier A, Guignard R, Leon C, Beck F. Effects of using an overlapping dual-frame design on estimates of health behaviors: a French general population telephone survey. J Surv Stat Methodol. 2017;5:254\u201374."},{"key":"4493_CR24","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.jhep.2018.05.017","volume":"69","author":"S Chevaliez","year":"2018","unstructured":"Chevaliez S, Pawlotsky JM. New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings. J Hepatol. 2018;69:916\u201326.","journal-title":"J Hepatol"},{"key":"4493_CR25","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1093\/infdis\/jiv423","volume":"213","author":"A Soulier","year":"2016","unstructured":"Soulier A, Poiteau L, Rosa I, Hezode C, Roudot-Thoraval F, Pawlotsky JM, et al. Dried blood spots: a tool to ensure broad access to hepatitis C screening, diagnosis, and treatment monitoring. J Infect Dis. 2016;213:1087\u201395.","journal-title":"J Infect Dis"},{"key":"4493_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1751-5823.2006.00002.x","volume":"75","author":"D Haziza","year":"2007","unstructured":"Haziza D, Beaumont J-F. On the construction of imputation classes in surveys. Int Stat Rev. 2007;75:25\u201343.","journal-title":"Int Stat Rev"},{"key":"4493_CR27","first-page":"33","volume":"23","author":"JL El Tinge","year":"1997","unstructured":"El Tinge JL, Yansaneh IS. Diagnostics for formation of nonresponse adjustment cells, with an application to income nonresponse in the US consumer expenditure survey. Surv Methodol. 1997;23:33\u201340.","journal-title":"Surv Methodol"},{"issue":"2","key":"4493_CR28","first-page":"139","volume":"54","author":"Roderick J. A. Little","year":"1986","unstructured":"Little RJ. Survey nonresponse adjustments for estimates of means. International Statistical Review\/Revue Internationale de Statistique. 1986;54:139\u201357.","journal-title":"International Statistical Review \/ Revue Internationale de Statistique"},{"key":"4493_CR29","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jclinepi.2013.10.017","volume":"67","author":"G Santin","year":"2014","unstructured":"Santin G, Geoffroy B, Benezet L, Delezire P, Chatelot J, Sitta R, et al. In an occupational health surveillance study, auxiliary data from administrative health and occupational databases effectively corrected for nonresponse. J Clin Epidemiol. 2014;67:722\u201330.","journal-title":"J Clin Epidemiol"},{"key":"4493_CR30","first-page":"41","volume":"77","author":"World Health Organization","year":"2002","unstructured":"World Health Organization. Global distribution of hepatitis a, B and C, 2001. Wkly Epidemiol Rec. 2002;77:41\u20138.","journal-title":"Wkly Epidemiol Rec"},{"key":"4493_CR31","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1136\/sextrans-2015-052090","volume":"92","author":"E Elliot","year":"2016","unstructured":"Elliot E, Rossi M, McCormack S, McOwan A. Identifying undiagnosed HIV in men who have sex with men (MSM) by offering HIV home sampling via online gay social media: a service evaluation. Sex Transm Infect. 2016;92:470\u20133.","journal-title":"Sex Transm Infect"},{"key":"4493_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta22220","volume":"22","author":"M Seguin","year":"2018","unstructured":"Seguin M, Dodds C, Mugweni E, McDaid L, Flowers P, Wayal S, et al. Self-sampling kits to increase HIV testing among black Africans in the UK: the HAUS mixed-methods study. Health Technol Assess (Winchester, England). 2018;22:1\u2013158.","journal-title":"Health Technol Assess (Winchester, England)"},{"key":"4493_CR33","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1471-2288-9-76","volume":"9","author":"P Bhatti","year":"2009","unstructured":"Bhatti P, Kampa D, Alexander BH, McClure C, Ringer D, Doody MM, et al. Blood spots as an alternative to whole blood collection and the effect of a small monetary incentive to increase participation in genetic association studies. BMC Med Res Methodol. 2009;9:76.","journal-title":"BMC Med Res Methodol"},{"key":"4493_CR34","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12885-015-1275-0","volume":"15","author":"AK Sakhi","year":"2015","unstructured":"Sakhi AK, Bastani NE, Ellingjord-Dale M, Gundersen TE, Blomhoff R, Ursin G. Feasibility of self-sampled dried blood spot and saliva samples sent by mail in a population-based study. BMC Cancer. 2015;15:265.","journal-title":"BMC Cancer"},{"key":"4493_CR35","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1186\/s12879-017-2776-z","volume":"17","author":"B Lange","year":"2017","unstructured":"Lange B, Roberts T, Cohn J, Greenman J, Camp J, Ishizaki A, et al. Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples - a systematic review and meta-analysis. BMC Infect Dis. 2017;17:693.","journal-title":"BMC Infect Dis"},{"key":"4493_CR36","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1186\/s12879-017-2777-y","volume":"17","author":"B Lange","year":"2017","unstructured":"Lange B, Cohn J, Roberts T, Camp J, Chauffour J, Gummadi N, et al. Diagnostic accuracy of serological diagnosis of hepatitis C and B using dried blood spot samples (DBS): two systematic reviews and meta-analyses. BMC Infect Dis. 2017;17:700.","journal-title":"BMC Infect Dis"},{"key":"4493_CR37","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1017\/S0950268816002934","volume":"145","author":"L Leon","year":"2017","unstructured":"Leon L, Kasereka S, Barin F, Larsen C, Weill-Barillet L, Pascal X, et al. Age- and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, 2004-2011: model-based estimation from two national cross-sectional serosurveys. Epidemiol Infect. 2017;145:895\u2013907.","journal-title":"Epidemiol Infect"},{"key":"4493_CR38","unstructured":"Pillonel J, Laperche S, Boulat C, Gallian P, Gross S, Roche C. Surveillance \u00e9pid\u00e9miologique des donneurs de sang, 1992-2016. \n                    https:\/\/www.santepubliquefrance.fr\/don-de-sang\/donnees\/#tabs\n                    \n                  . Accessed 2 Dec 2018."},{"key":"4493_CR39","unstructured":"Poethko-Muller C, Zimmermann R, Hamouda O, Faber M, Stark K, Ross RS, et al. Epidemiology of hepatitis a, B, and C among adults in Germany: results of the German health interview and examination survey for adults (DEGS1). Bundesgesundheitsblatt, Gesundheitsforschung. Gesundheitsschutz. 2013;56:707\u201315."},{"key":"4493_CR40","unstructured":"Vaux S, Laporal S, Pioche C, Brouard C, Lot F. H\u00e9patites B et C, derni\u00e8res donn\u00e9es \u00e9pid\u00e9miologiques. Journ\u00e9e nationale de lutte contre les h\u00e9patites virales B et C, 2018.\u00a0\n                    https:\/\/solidarites-sante.gouv.fr\/IMG\/pdf\/1-presentation_s_vaux.pdf\n                    \n                  . Accessed 1 Dec 2018."},{"key":"4493_CR41","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1186\/1471-2458-13-576","volume":"13","author":"C Brouard","year":"2013","unstructured":"Brouard C, Gautier A, Saboni L, Jestin C, Semaille C, Beltzer N. Hepatitis B knowledge, perceptions and practices in the French general population: the room for improvement. BMC Public Health. 2013;13:576.","journal-title":"BMC Public Health"},{"key":"4493_CR42","unstructured":"Brouard C, Gautier A, Vaux S, Richard J-B. Sentiment d'information et pratiques d\u00e9clar\u00e9es de d\u00e9pistage vis-\u00e0-vis des h\u00e9patites B et C en population g\u00e9n\u00e9rale ultramarine. Enqu\u00eate Barom\u00e8tre sant\u00e9 DOM 2014. Bull Epidemiol Hebd 2018:204-209."},{"key":"4493_CR43","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/jech.2009.101378","volume":"66","author":"A Origer","year":"2012","unstructured":"Origer A, Schmit JC. Prevalence of hepatitis B and C and HIV infections among problem drug users in Luxembourg: self-report versus serological evidence. J Epidemiol Community Health. 2012;66:64\u20138.","journal-title":"J Epidemiol Community Health"},{"key":"4493_CR44","doi-asserted-by":"crossref","unstructured":"Boyd A, Gozlan J, Carrat F, Rougier H, Girard PM, Lacombe K, et al. Self-reported patient history to assess hepatitis B virus serological status during a large screening campaign. Epidemiol Infect. 2018:1\u20138.","DOI":"10.1017\/S0950268818002650"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4493-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4493-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4493-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T20:12:03Z","timestamp":1603743123000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4493-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,28]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4493"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4493-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.12732\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.12732\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.12732\/v2","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,28]]},"assertion":[{"value":"5 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"For the 2016-HB (phone survey), consent was obtained orally from the participants (and also from the parents or guardians for participants under 16\u2009years old) to answer the phone interview and, at the end of the interview, to receive the self-sampling kit. For BaroTest (virological sub-study), consent was obtained using a written informed consent, that was sent back by the participant to the laboratory with the DBS. The research protocol was validated by the Committee for the protection of the persons (CPP), the French ethical committee for biomedical research (no. 2015-A01252-47).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"896"}}